Customize POT13 Antibody

Description

Clarification of Terminology

The designation "POT13" does not correspond to any documented antibody, protein target, or clinical compound in current immunological or pharmacological databases. Potential scenarios include:

Typographical error (e.g., "POT13" vs. "POTE13" or "POST13")
Misinterpretation of nomenclature for validated antibodies (e.g., PGT121 , VRC07-523LS , or CM313 )
Reference to a proprietary or experimental compound not yet published.

Analysis of Similar Antibody Designations

Relevant antibodies with numerical identifiers in the search results include:

Antibody Name	Target/Function	Key Findings
PGDM1400	HIV-1 V2-glycan epitope	Reduced viremia in HIV patients but led to viral rebound within 20 days.
CM313	CD38 antigen	Demonstrated potent CDC/ADCC activity in multiple myeloma preclinical models.
Anti-ADAMTS13	ADAMTS13 protease in thrombotic disorders	Inhibitory autoantibodies linked to thrombotic thrombocytopenic purpura.
Anti-nsp13	Porcine epidemic diarrhea virus (PEDV)	Monoclonal antibodies 5A9/5C7/5G7 characterized for viral replication studies.

None align with "POT13" in naming convention or mechanism.

Research Gaps and Recommendations

To address the absence of data on "POT13 Antibody":

Verify nomenclature with primary sources or collaborators.
Explore related antibodies targeting interleukin-13 (IL-13), thrombospondin type-1 domain-containing protein 13 (THSD13), or other "13"-designated biomolecules.
Consult specialized databases:
- UniProt (uniprot.org) for protein identifiers
- ClinicalTrials.gov for ongoing antibody studies
- WHO International Nonproprietary Names (INN) for antibody naming standards.

Methodological Framework for Antibody Characterization

If "POT13" represents a novel antibody, standard validation steps include:

Step	Technique/Assay	Purpose
Epitope Mapping	Surface plasmon resonance (SPR)	Identify binding domains
Functional Activity	Neutralization assays , ADCC/CDC	Assess pathogen inhibition or cell lysis
Pharmacokinetics	PBPK modeling , ELISA	Predict tissue distribution and half-life
Preclinical Safety	Cynomolgus monkey trials	Evaluate toxicity and immunogenicity

Implications of Non-Detection

The absence of "POT13 Antibody" in indexed literature suggests:

Experimental stage: The antibody may be in early development without public data.
Terminology mismatch: Potential alignment with antibodies like Trop-2-targeted sacituzumab govitecan or anti-CD38 CM313 .
Discontinued research: Previous candidates (e.g., failed Phase I trials) may lack published results.

Product Specs

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4

Form

Liquid

Lead Time

Made-to-order (14-16 weeks)

Synonyms

POT13 antibody; KT5 antibody; KUP5 antibody; At4g33530 antibody; F17M5.1 antibody; T16L1.20 antibody; Potassium transporter 13 antibody; AtKT5 antibody; AtPOT13 antibody

Target Names

POT13

Uniprot No.

Q8LPL8

Target Background

Function

This antibody targets a protein that is likely involved in potassium transport.

Database Links

KEGG: ath:AT4G33530

STRING: 3702.AT4G33530.1

UniGene: At.42962

Protein Families

HAK/KUP transporter (TC 2.A.72.3) family

Subcellular Location

Cell membrane; Multi-pass membrane protein.

Q&A

Given the potential typographical error ("POT13" instead of "KRT13" or "Cytokeratin 13"), this FAQ collection focuses on Cytokeratin 13 (KRT13) antibodies, leveraging academic research insights from the provided sources. Below are structured questions addressing experimental design, data interpretation, and advanced research challenges.

Advanced Research Questions

How to resolve conflicting data between Cytokeratin 13 western blot and IHC results?
- Step 1: Verify post-translational modifications (PTMs) in samples, as epitope accessibility may vary between denatured (western blot) and native (IHC) states.
- Step 2: Assess tissue fixation methods; over-fixation in formalin may mask epitopes, requiring antigen retrieval optimization .
- Step 3: Cross-validate with orthogonal methods (e.g., RNA in situ hybridization for KRT13 mRNA) .
What strategies mitigate batch variability in polyclonal Cytokeratin 13 antibodies?
- Transition to recombinant monoclonal antibodies (e.g., clone EPR3671) for defined epitope recognition and supply stability .
- For legacy polyclonal stocks, pre-validate each batch using standardized TMAs and knockout controls .

Data Analysis and Interpretation

How to design a robust experiment analyzing Cytokeratin 13’s role in mechanical stress response?
- Model system: Use primary human tongue mucosal cells under cyclic strain or compression .
- Endpoints: Quantify G1/S phase cyclins (CCNE1/CCNE2) via qPCR or flow cytometry to link KRT13 to cell cycle regulation .
- Controls: Include siRNA-mediated KRT13 knockdown and rescue experiments.
What statistical approaches address variability in antibody-dependent T cell activation assays?
- Apply mixed-effects models to account for donor-specific PBMC variability (e.g., baseline IL-2 secretion) .
- Normalize data to pre-treatment T cell counts to isolate treatment effects .

Comparative Methodologies

Parameter	Monoclonal Antibodies	Recombinant Antibodies
Specificity	Single epitope recognition	Defined sequence, engineered
Batch variability	Low	Minimal
Applications	High-specificity assays	Multi-omics integration

Troubleshooting Guide

Why does Cytokeratin 13 antibody staining show non-specific signals in FFPE tissues?
- Cause: Incomplete antigen retrieval or endogenous biotin activity.
- Solution: Optimize heat-mediated retrieval (pH 6.0 citrate buffer) and block with 3% BSA/5% normal serum .
How to interpret discordant flow cytometry results across replicates?
- Re-evaluate gating strategies using fluorescence-minus-one (FMO) controls.
- Confirm antibody stability (e.g., avoid freeze-thaw cycles for recombinant antibodies) .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

POT13 Antibody